Ligand Pharmaceuticals trades as part of the healthcare sector and is part of the biotechnology industry. The company CEO is John L. Higgins. Ligand Pharmaceuticals Inc is a biopharmaceutical company. Its business model is based upon the concept of acquiring royalty revenue generating assets and coupling them with a lean corporate cost structure.
Previous Intraday Trading Performance:
The LGND stock showed a previous change of 3.13% with an open at 110.87 and a close of 113.78. It reached an intraday high of 114.16 and a low of 109.68.
The stock has a market cap of $2.2b with 19.6m shares outstanding, of which the float is 18.1m shares. Trading volume reached 263,294 shares compared to its average volume of 322,003 shares. Based on the current average volume and close price, the trading liquidity is good.
Historical Trading Performance:
Over the last five trading days, Ligand Pharmaceuticals shares returned 0.19% and in the past 30 trading days it returned -10.49%. Over three months, it changed 2.52%. In one year it has changed -40.93% and within that year its 52-week high was 278.62 and its 52-week low was 98.56. LGND stock is 15.44% above its 52 Week Low.
Our calculations show a 200 day moving average of 154.25 and a 50 day moving average of 119.21. Currently LGND stock is trading -26.24% below its 200 day moving average and may not be a good opportunity to buy as it may continue to trend down.
The last annual fiscal EPS for the company was reported at 5.97 that ended on 31st of December 2018, which according to the previous close, that is a PE of 19.06. Based on 1 analyst estimate, the estimated EPS for the next quarter is 0.88. The TTM EPS is 6.55, which comes to a TTM PE of 17.37.
Below was the last reported quarterly diluted earnings per share:
|1st||Qtr of 2019||(Reported on 05/02/2019):||31.32|
|4th||Qtr of 2018||(Reported on 02/07/2019):||-2.02|
|3rd||Qtr of 2018||(Reported on 11/08/2018):||2.80|
|2nd||Qtr of 2018||(Reported on 08/06/2018):||2.99|
|1st||Qtr of 2018||(Reported on 05/08/2018):||1.83|
Base on our calculations, the intrinsic value per share is 76.83, which means it may be overvalued by -48.09%.
Indicators to Watch:
The current calculated beta is 1.41.
Based on last reported financials, the company’s return on equity is 100.70%, return on assets is 58.77%, price-to-sales is 9.06 and price-to-book is 2.00.
All scores are out of six:
3 :Valuation Score
6 :Past Performance Score
4 :Financial Strength Score
0 :Future Growth Score
0 :Dividend Score
3 :Overall Score